Agence France-Presse3d
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...
Morningstar3d
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
Nervous System: Meningitis, encephalitis ... The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040 ...
pharmaphorum5d
GSK has most to prove after $16 bn Novartis deal
Other drugs in the portfolio include Votrient, for renal cell carcinoma, Promacta for thrombocytopenia ... a new vaccine to prevent meningitis B, with a further candidate vaccine in late-stage ...
BeiGene, Ltd.: TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
New indication based on results from a global Phase 3 trial demonstrating significantly improved overall survival benefit for PD-L1 positive patients treated with TEVIMBRA in combination with chemothe ...
Medindia1d
Create a Medindia Widget
The rising trend in health and lifestyle related problems in the world warrants us to be well informed and health-conscious of the latest happenings in this field. Medindia offers a freely ...
Science Daily2d
Vaccines News
Feb. 26, 2025 — Pre-existing immunity against seasonal H1N1 flu might help explain why most reported human cases of H5N1 bird flu in the U.S. have not resulted in lethal ...